Sakar Healthcare Ltd
Incorporated in 2004, Sakar Healthcare Ltd is in the business of manufacturing Research & Development of Pharmaceutical products[1]
- Market Cap ₹ 695 Cr.
- Current Price ₹ 317
- High / Low ₹ 374 / 210
- Stock P/E 39.6
- Book Value ₹ 130
- Dividend Yield 0.00 %
- ROCE 8.58 %
- ROE 6.40 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 6.50% over last 3 years.
- Promoter holding has decreased over last 3 years: -14.0%
- Working capital days have increased from 62.8 days to 96.3 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
30 | 35 | 41 | 44 | 53 | 68 | 83 | 95 | 128 | 133 | 153 | 178 | |
22 | 27 | 33 | 34 | 40 | 51 | 63 | 72 | 99 | 100 | 115 | 128 | |
Operating Profit | 8 | 8 | 8 | 10 | 13 | 17 | 20 | 23 | 29 | 33 | 38 | 50 |
OPM % | 26% | 22% | 20% | 23% | 24% | 25% | 24% | 24% | 23% | 25% | 25% | 28% |
0 | 0 | 0 | 1 | 0 | 1 | 2 | 1 | 2 | 5 | 3 | 1 | |
Interest | 4 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 6 | 8 | 9 |
Depreciation | 2 | 2 | 3 | 3 | 4 | 6 | 7 | 8 | 10 | 15 | 18 | 21 |
Profit before tax | 2 | 2 | 3 | 5 | 6 | 9 | 12 | 13 | 19 | 17 | 16 | 22 |
Tax % | 13% | 24% | 22% | 30% | 38% | 28% | 21% | 19% | 20% | 24% | 27% | 19% |
2 | 2 | 2 | 3 | 4 | 7 | 10 | 11 | 15 | 13 | 12 | 18 | |
EPS in Rs | 2.19 | 2.30 | 2.78 | 3.08 | 3.12 | 4.47 | 6.43 | 6.84 | 8.90 | 6.70 | 5.37 | 7.97 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 18% |
5 Years: | 16% |
3 Years: | 11% |
TTM: | 16% |
Compounded Profit Growth | |
---|---|
10 Years: | 25% |
5 Years: | 13% |
3 Years: | 5% |
TTM: | 53% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 44% |
3 Years: | 24% |
1 Year: | -10% |
Return on Equity | |
---|---|
10 Years: | 9% |
5 Years: | 8% |
3 Years: | 7% |
Last Year: | 6% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 8 | 8 | 8 | 11 | 12 | 15 | 15 | 16 | 17 | 19 | 22 | 22 |
Reserves | 6 | 7 | 11 | 25 | 39 | 57 | 66 | 83 | 110 | 154 | 241 | 264 |
24 | 25 | 22 | 24 | 11 | 11 | 17 | 43 | 93 | 119 | 79 | 75 | |
14 | 11 | 10 | 11 | 18 | 15 | 17 | 37 | 47 | 44 | 47 | 55 | |
Total Liabilities | 52 | 50 | 51 | 71 | 81 | 97 | 115 | 178 | 268 | 336 | 389 | 415 |
38 | 36 | 37 | 49 | 53 | 64 | 66 | 69 | 205 | 267 | 314 | 309 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 9 | 13 | 49 | 1 | 6 | 0 | 17 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 3 | 0 | 0 |
14 | 14 | 14 | 22 | 28 | 25 | 36 | 60 | 55 | 60 | 74 | 89 | |
Total Assets | 52 | 50 | 51 | 71 | 81 | 97 | 115 | 178 | 268 | 336 | 389 | 415 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
9 | 4 | 9 | 2 | 5 | 16 | 19 | 15 | 36 | 33 | 24 | 34 | |
-3 | -1 | -4 | -14 | -8 | -25 | -22 | -47 | -90 | -74 | -52 | -31 | |
-6 | -3 | -6 | 13 | -13 | 9 | 3 | 32 | 55 | 41 | 27 | -3 | |
Net Cash Flow | -0 | 1 | -1 | 0 | -16 | 0 | -0 | -0 | -0 | 0 | 0 | -0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 28 | 21 | 26 | 44 | 74 | 51 | 36 | 48 | 40 | 60 | 50 | 63 |
Inventory Days | 190 | 142 | 107 | 114 | 51 | 70 | 92 | 112 | 69 | 76 | 121 | 193 |
Days Payable | 97 | 20 | 66 | 51 | 57 | 41 | 46 | 141 | 149 | 129 | 120 | 93 |
Cash Conversion Cycle | 120 | 143 | 67 | 107 | 68 | 80 | 83 | 19 | -39 | 7 | 51 | 163 |
Working Capital Days | 75 | 89 | 45 | 110 | 108 | 46 | 41 | 8 | 2 | 30 | 62 | 96 |
ROCE % | 15% | 14% | 14% | 15% | 14% | 16% | 16% | 13% | 12% | 9% | 7% | 9% |
Documents
Announcements
-
Statement of deviation(s) or variation(s) under Reg. 32
15 May 2025 - No deviation in utilization of Rs.5.76 Cr from preferential issue as of 31-03-2025.
-
Outcome of Board Meeting
15 May 2025 - Sakar Healthcare reports audited FY25 standalone and consolidated results with profit of Rs 1750 lakh, up from Rs 1167 lakh.
-
Outcome of Board Meeting
15 May 2025 - Audited FY25 standalone and consolidated financial results with unmodified audit opinion disclosed.
-
Board Meeting Intimation
9 May 2025 - SAKAR HEALTHCARE LIMITED has informed about Board Meeting to be held on 15-May-2025 to inter-alia consider and approve the Audited Financial results of the Company …
-
Disclosure under SEBI Takeover Regulations
7 May 2025 - Sanjay S. Shah has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, …
Annual reports
Concalls
-
Oct 2022TranscriptNotesPPT
Business Overview:[1][2][3]
SHL, certified by ISO 9001:2015 (BVQI), WHO-GMP, cGMP, and the National Drug Authority, provides comprehensive healthcare and pharmaceutical products. Operating in over 50 countries with 292 registered products and 210 more under registration, SHL partners with 70+ overseas distributors. The company also engages in contract manufacturing for leading domestic brands and direct sales in both domestic and export markets.